1. Search Result

Search Result

Targets Recommended: CRISPR/Cas9

Results for "5690-03-9" in MCE Product Catalog:

Cat. No. Product Name Target Research Area
  • HY-100585


    HDAC Cancer
    Splitomicin (Splitomycin) is a selective Sir2p inhibitor. Splitomicin inhibits NAD +-dependent HDAC activity of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast extract with an IC50 of 60 μM.